Single Cell Analysis Market

The global Single Cell Analysis Market was valued at USD 2.30 Billion in 2022 and is projected to reach a value of USD 6.99 Billion by 2030 at a CAGR (Compound Annual Growth Rate) of 14.90% between 2023 and 2030.

Market Synopsis:

Global Single Cell Analysis market is valued at USD 2.30 Billion in 2022 and is projected to attain a value of USD 6.99 Billion by 2030 at a CAGR of 14.90% during the forecast period, 2022–2028. The market's rise may be ascribed to an increase in investments and government money allocated to medical diagnostics research and development (R&D), the availability of technically improved products, and the increased usage of Single Cell Analysis equipment. Furthermore, advances in Single Cell Analysis amplification and modification techniques have resulted in the use of high-throughput technologies in assays, resulting in revenue increase. Furthermore, the rapid development of microfluidic equipment has considerably expanded the use of Single Cell Analysis genomic/transcriptomic analysis in biomedical research.

Most businesses have been working on the development of cell-based therapeutics for COVID-19 treatment, the impact of the COVID-19 pandemic on the Single Cell Analysis market is projected to be enormous. To better construct prognostic and diagnostic indicators and establish appropriate therapeutic approaches for patients with severe disease presentation, a better understanding of the host immune response throughout disease progression is critical. Single-cell analysis can help researchers better understand immune cells on a single-cell level, as well as how functional cells contribute to immune protection and pathogenesis, allowing for the development of more effective vaccines and immunotherapies.

Growing Prevalence of Cancer

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Cancer genomics is one of the most important applications of single-cell analysis. According to GLOBOCAN, cancer cases would increase to almost 30 million by 2040, up from 19.3 million cases and ten million cancer deaths in 2020. Because of the rising frequency of this disease, more study is needed for diagnosis and treatment; single-cell analysis is an important aspect of this research. Individual cell analysis allows for accurate illness diagnosis and therapy efficacy monitoring. In breast cancer and other malignancies, single-cell analysis aids in the identification of helper T-cells, the detection of DNA content, and the monitoring of tumour cell proliferation.

High Cost of Single-Cell Analysis Products

Because of the requirement to maintain high-quality standards (the use of high-grade, expensive items) and adhere to regulatory rules, single-cell biology research has a high cost. However, due to funding constraints, research and academic laboratories are unable to purchase such expensive instruments. In addition, the total cost of ownership of these instruments rises as a result of maintenance charges and a variety of additional indirect expenses. This is a key stumbling block to the widespread use of flow cytometers and microfluidic devices in clinical and research settings.

Market Segmentation:

Global Single Cell Analysis market is segmented on the basis of Product into Consumables and Instruments. Based on Application into Cancer, Immunology, Neurology, Stem cell, Non-invasive prenatal diagnosis, In-vitro fertilization and Others. By End-Use into Academic & Research Laboratories, Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostic Laboratories and Others. Based on region, the Single Cell Analysis market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

North America to Continue Dominating the Single Cell Analysis Market

In 2020, North America dominated the Single Cell Analysis market over the forecast period. High government financing, increased personal healthcare expenditures, improved awareness, rapid adoption of novel analytical techniques, and the availability of competent employees can all be contributed to this. The United States is a big contributor to North America's dominance. Exceptionally well-developed healthcare infrastructure, expanding spending on personalized medicine, rising public awareness, and increased government and private support for research projects are some of the market's primary driving forces. Factors including the burgeoning medical tourism business, fast improving healthcare infrastructure, and rising disposable income have fueled demand for modern diagnostic technologies in Asia Pacific's emerging nations in recent years.